NKMAX Co. Ltd.
KOE: 182400.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sangwoo Park
- Employees
- 134
- Headquarters
- Seongnam-si, South Korea
- IPO year
- 2015
- Market cap
- ₩172.7B
- Website
- https://www.nkmax.com
Loading 182400…
Loading profile data…Frequently asked questions about 182400
What does NKMAX Co. Ltd. (182400.KQ) do?
NKMAX CO., Ltd. manufactures and sells biological products in South Korea. The company offers anti-cancer immunotherapy treatment that activates the immune cells in body to kill the cancer cells; natural killer cell activity test for cancer patients; NK VUE Kit, an NK cell activity test that quantitatively measures IFN-gamma released from activa...
Where does 182400.KQ trade?
NKMAX Co. Ltd. (182400.KQ) trades on the KOSDAQ.
What sector is 182400.KQ in?
NKMAX Co. Ltd. (182400.KQ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NKMAX Co. Ltd.?
Sangwoo Park is the chief executive officer of NKMAX Co. Ltd. (182400.KQ).
Where is NKMAX Co. Ltd. headquartered?
NKMAX Co. Ltd. is headquartered in South Korea.
Does 182400.KQ pay a dividend?
NKMAX Co. Ltd. (182400.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 182400.KQ go public?
NKMAX Co. Ltd. (182400.KQ) completed its initial public offering in 2015.